Company Overview
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.
Why Investors Should Care
Revenue has grown at a 15.9% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $56.20M (+17.7% YoY); net profit $19.49M.
- Trailing 12 Months Year-on-year growth — revenue +13.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 15.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 15.88% |
| 1 Year: | 13.60% |
Stock Price Performance
| 1 Year: | +42.55% |
| 6 Months: | +60.54% |
| 3 Months: | +26.73% |
| 1 Month: | +21.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.27 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 15.9% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MASS 908 Devices Inc. R2KR3KPHARMA | 10.05 | -10.36 | $412.32M | 0.00% | -25.27% | -24.11% | 15.88% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.00M | 11.13M | 6.05M | 5.54M | 8.28M | 12.54M | 8.31M | 11.11M | 15.80M | 9.49M | 12.09M | 14.30M | 7.42M | 11.46M | 14.52M | 11.78M | 13.04M | 14.01M | 13.38M |
| Gross Profit | 2.10M | 6.41M | 3.84M | 2.91M | 4.38M | 6.81M | 4.13M | 6.63M | 9.34M | 4.38M | 5.79M | 7.87M | 3.89M | 6.16M | 7.78M | 5.54M | 6.37M | 7.36M | 6.88M |
| Operating Income | -2.76M | 2.13M | -1.29M | -5.81M | -7.46M | -5.28M | -9.52M | -8.37M | -7.15M | -13.02M | -10.94M | -9.09M | -7.61M | -8.54M | -24.49M | -11.03M | -15.16M | -16.32M | -12.88M |
| Net Income | -2.97M | 2.10M | -1.72M | -6.09M | -7.42M | -5.18M | -9.41M | -8.10M | -6.26M | -12.53M | -9.35M | -7.09M | -10.92M | -12.55M | -29.30M | 43.60M | -13.31M | -14.98M | -11.96M |
| Diluted EPS | -0.60 | 0.10 | -0.34 | -0.22 | -0.27 | -0.19 | -0.30 | -0.26 | -0.20 | -0.39 | -0.29 | -0.22 | -0.33 | -0.37 | -0.84 | 1.23 | -0.37 | -0.41 | -0.32 |
| R&D Expense | 2.16M | 1.85M | 1.95M | 2.96M | 3.06M | 3.30M | 3.90M | 4.29M | 4.67M | 5.40M | 5.53M | 5.54M | 3.29M | 3.59M | 4.21M | 3.83M | 4.41M | 3.84M | 3.47M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 26.89M | 42.21M | 46.85M | 50.23M | 47.75M | 56.20M |
| Gross Profit | 14.92M | 23.23M | 26.02M | 25.32M | 24.50M | 28.42M |
| Operating Income | -5.82M | -22.07M | -35.38M | -42.76M | -57.39M | -39.42M |
| Net Income | -12.82M | -22.17M | -33.56M | -36.40M | -72.21M | 19.49M |
| Diluted EPS | -2.35 | -0.79 | -1.07 | -1.13 | -2.12 | 0.54 |
| R&D Expense | 8.23M | 13.07M | 17.53M | 21.90M | 14.99M | 15.57M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 178.83M | 260.91M | 242.59M | 202.98M | 159.48M | 190.07M |
| Total Equity | -63.17M | 139.04M | 214.60M | 190.60M | 165.49M | 114.59M | 143.70M |
| Cash & Equivalents | - | 159.23M | 224.07M | 188.42M | 121.04M | 44.03M | 70.52M |
| Long Term Debt | - | 14.33M | 15.00M | 15.00M | - | - | - |
| Total Liabilities | - | 39.79M | 46.30M | 51.99M | 37.49M | 44.88M | 46.37M |
| Current Liabilities | - | 10.83M | 14.84M | 19.23M | 22.55M | 25.15M | 34.06M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.13M | -29.08M | -20.93M | -25.06M | -30.25M | -23.69M |
| Investing Cash Flow | -9.00K | -737.00K | -15.81M | -26.40M | -46.32M | 50.75M |
| Financing Cash Flow | 137.19M | 94.72M | 1.18M | -15.94M | -376.00K | -697.00K |
| Capital Expenditure | -9.00K | -737.00K | -2.04M | -2.04M | -602.00K | -955.00K |
| Free Cash Flow | 4.12M | -29.82M | -22.98M | -27.10M | -30.85M | -24.64M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 55.5% | 55.0% | 55.5% | 50.4% | 51.3% | 50.6% |
| Operating Margin % | -21.6% | -52.3% | -75.5% | -85.1% | -120.2% | -70.1% |
| Net Margin % | -47.7% | -52.5% | -71.6% | -72.5% | -151.2% | 34.7% |
| ROE % | -9.2% | -10.3% | -17.6% | -22.0% | -63.0% | 13.6% |
| ROCE % | -3.5% | -9.0% | -15.8% | -23.7% | -42.7% | -25.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | First Light Asset Management, LLC | 15.20% | 6.28M | $67.41M |
| 2 | AWM Investment Company, Inc. | 11.81% | 4.88M | $52.36M |
| 3 | ARK Investment Management, LLC | 4.91% | 2.03M | $21.76M |
| 4 | Blackrock Inc. | 4.70% | 1.94M | $20.86M |
| 5 | Needham Investment Management, L.L.C. | 4.40% | 1.82M | $19.54M |
| 6 | Vanguard Capital Management LLC | 3.12% | 1.29M | $13.86M |
| 7 | First Eagle Investment Management, LLC | 2.25% | 929.99K | $9.98M |
| 8 | Geode Capital Management, LLC | 1.84% | 761.80K | $8.17M |
| 9 | Granahan Investment Management LLC | 1.67% | 692.09K | $7.43M |
| 10 | State Street Corporation | 1.47% | 606.56K | $6.51M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MASS
Avoiding Lag: Real-Time Signals in (MASS) Movement - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQNHM4R0QtRl9aOHEzdUdyUDcwd1RfTTVBRmxmV0FSa1VmRFVJZU5DV0ZXT1M0Y01VZXhXVVk4WlphNjBUeC0tb05VM29OVUw3RzJxZUd1VkM1V092Tkt0TGhUcUZvUUpHbnctbDhNXzJUTVVpcVVOS0ZZS2VHczZMX3dCZWIwNUV5MlFnM3…
Director at 908 Devices (NASDAQ: MASS) sells 30,000 shares under 10b5-1 plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNZVJibGlTYUI4NkpBMDhOUzBWeXZsMlJDMy1aUVk3ODhVR3h3S0hKaEpqRjlCcjNYQms4TDB4WlVKSGtaYkhxbzVkUEZfUzM0cHZCUUNoZEdlYUFaX2tUaGdQY1hoc3h5bzJJZUpaY3dZMjQwT0FtZXZ2amhWS2FQeDBOb1YyUjA0YVpaaD…
EVTC vs. MA: Which Stock Is the Better Value Option? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOUktFWHh0YWtBb2l6Sl9fR3V1eVlnRnZwOVk0ZXVZSjk0T0JTcHFHZ3p1alFuaFdEeFZaamJZWkpaMWdKNGFucE1JeGVvOEdFY2pwQ1h2djNFOGhLSDJpVXY4YWpQY25rN2ZWUkl6TXZHMkY4MmR0V0NYRnJKWUowa05uLUk5X19HTjFvZ2…
$MASS stock is up 10% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQcWU3Nk1jRlplRHpsSkZUV2ViSXlLLWp1cWk5WkVtQ0hGb3VnNWtpS1BUYk5ONXhCV3VZRUVFWENfZWtSV00tazdpaWN3MVJXaG16bGdwZUlNZWZyeVg4U2swZlc4eERzQ3AxeV9LZmlKbmp2RF9KQnN1dnRCNmJrWnc5cTNRRlF4a0pMZ0…
Suffolk County sheriff acquitted of extortion charges in cannabis company stock case - MassLive
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPRGd4VHBhelJObGE2SWhYNjIzakdNdnpUS09PZ2ItYnd0OElzYUQ1c044dG5pVTgzeHlSZDBTbWE3YXU3Rjk1WDFmNVZlVG9SM0xwVFI1NDEzSGNaeTYwdTRNdS1ZM2x0YllsZGR5NjJ6RTNXMmcyYnRFRUJOSlByNk5HbGNLZ2xDbjFWWk…
With Its First Mass-Market Vehicle Launching, Is Rivian Stock Ready To Turn The Corner? - Trefis
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNQWc3NHQ2ZmYyN1ZXRWpQUnZNZGpKRzNnWThjdGhGM1FJc0UwMW9GMWxEczlJb2hkdjl6TV8xWW8tS0Y2MFZNc2RIM0JLR1hLYldVMXRFS1pVX2NpQXk3MlU2YUNCdlo1QmpoT3d5Nm5TeElYdnIxb2JWc1U3clBWZ0JrZVFPaWNGdVZHMD…
MASS — Frequently Asked Questions
What is the current share price of 908 Devices Inc. (MASS)?
As of 2026-09-07 16:24 PDT, 908 Devices Inc. (MASS) trades at $10.05 on NasdaqGM. Its 52-week range is $5.09 to $11.10.
What is the market capitalisation of MASS?
908 Devices Inc. (MASS) has a market capitalisation of $412.32M on NasdaqGM.
What is the P/E ratio of MASS?
MASS trades at a trailing price-to-earnings (P/E) ratio of -10.36. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.48.
What is the return on equity (ROE) of MASS?
MASS has a return on equity (ROE) of -24.11%. Its return on capital employed (ROCE) is -25.27%.
Is MASS a good stock to buy?
This page provides a data-driven analysis of 908 Devices Inc. (MASS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.